Meir Medical Center
Welcome,         Profile    Billing    Logout  
 129 Trials 
688 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Contact, Site Public
NCT03630536: TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative

Recruiting
N/A
500
US
Children's Hospital Medical Center, Cincinnati
Renal Cell Carcinoma
05/28
05/28
NCT05705531: A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

Recruiting
N/A
230
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Electronic Health Record Review, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Survey Administration
Children's Oncology Group, National Cancer Institute (NCI)
Cardiovascular Disorder, Clonal Hematopoiesis, Hodgkin Lymphoma
10/28
10/28
NCT05702645: A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

Recruiting
N/A
330
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Clinical Evaluation, Clinical Assessment, Questionnaire Administration, Survey Administration
Children's Oncology Group, National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
12/28
12/28
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting
N/A
207
Europe, US, RoW
ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855
Baxalta now part of Shire
Hemophilia A
02/30
02/30
EA2185, NCT04239573: Comparing Two Methods to Follow Patients With Pancreatic Cysts

Recruiting
N/A
4606
Canada, US, RoW
Computed Tomography, CAT, CAT scan, Computerized Axial Tomography, computerized tomography, CT, CT scan, tomography, Endoscopic Ultrasound, endosonography, EUS, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, nuclear magnetic resonance imaging, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Pancreatic Carcinoma
07/33
07/33
PARADIGHM, NCT01922440: A Registry for Participants With Chronic Hypoparathyroidism

Active, not recruiting
N/A
1340
Europe, Canada, US
No intervention
Takeda, Takeda Development Center Americas, Inc.
Hypoparathyroidism
11/34
11/34
SWOG-S1703, NCT03723928: S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Recruiting
N/A
739
US, RoW
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, STMDDM, Quality-of-Life Assessment, Quality of Life Assessment, Anxiety Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
12/30
12/36
FORTE, NCT05080673: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Recruiting
N/A
9500
US
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
NRG Oncology, National Cancer Institute (NCI)
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
11/35
11/65
SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
N/A
2262
US, RoW
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU
NRG Oncology, National Cancer Institute (NCI)
Ovarian Carcinoma
06/36
06/37
NCT00904241: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Recruiting
N/A
10000
Europe, Canada, US, RoW
Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
01/00
 
AREN03B2, NCT00898365: Study of Kidney Tumors in Younger Patients

Recruiting
N/A
8000
Europe, Canada, US, RoW
Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
01/00
 
NCT00736749: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Recruiting
N/A
5000
US
Assessment of Therapy Complications, Questionnaire Administration
Children's Oncology Group, National Cancer Institute (NCI)
Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
01/00
 
Lev, Nirit
NCT05822908 / 2022-001314-19: A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

Recruiting
1/2
65
Europe, RoW
VO659
Vico Therapeutics B. V., VICO Therapeutics B.V.
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
09/25
09/25
Rao, Pooja
AYA-UNITE, NCT03778658: Utilizing Novel Information Technology to Promote Exercise and Well-Being in Adolescents and Young Adults With Cancer

Completed
N/A
7
US
Physical Activity Intervention
Milton S. Hershey Medical Center
Adolescent, Young Adult, Cancer, Physical Activity, Psychological Distress, Social Isolation
09/22
09/22
FAST, NCT06174649: Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial

Recruiting
N/A
900
Europe, RoW
Reveal
Duke University, National Institute of Allergy and Infectious Diseases (NIAID), Parexel, BioMérieux
Gram-negative Bacteremia, Bloodstream Infection
05/25
06/25
Alessio, Maria
NCT04527380 / 2018-000681-10: A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Active, not recruiting
3
100
Europe, RoW
Ixekizumab, LY2439821, Adalimumab
Eli Lilly and Company
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
02/24
04/28
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
10/25
10/25
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
12/30
12/30
Uziel, Yosef
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
10/25
10/25
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
12/30
12/30
Rabinowicz, Noa
NCT03473912: Meir Medical Center Rheumatologic Biobank

Recruiting
N/A
500
RoW
Meir Medical Center
Rheumatoid Arthritis, Lupus Erythematosus, Systemic, Systemic Sclerosis, IgG4-related Disease, Sjogren's Syndrome
11/37
11/37
Maor, Gil Shechter
NCT05782296: Noninvasive Monitoring of Uterine Activity and Fetal Heart Rate

Recruiting
N/A
100
US, RoW
TrueLabor
OB-Tools Ltd.
Fetal Heart Rate or Rhythm Abnormality Affecting Newborn During Labor, Uterine Contractions, Obstetric Complication
04/24
04/24
Vishlitzky, Victor
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Not yet recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT04608305: Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine

Completed
1/2
843
RoW
IIBR-100, low dose (prime), IIBR-100 medium dose (prime), IIBR-100 high-dose (prime), IIBR-100 low-dose (prime-boost), Saline Placebo (single), Saline Placebo (double), IIBR-100 medium-dose (prime-boost), IIBR-100 high-dose (prime-boost), IIBR-100 top-dose (prime-boost)
Israel Institute for Biological Research (IIBR)
Covid19
10/22
10/22
Zifman, Eyal
Asableach, NCT06013696: Bleach and Urine Color in UC Patients Using 5ASA

Active, not recruiting
N/A
40
RoW
Adding household bleach to urine sample
Meir Medical Center
Ulcerative Colitis
08/24
12/24
NCT06017856: Physical Exercise and Nutrition in Functional Gastrointestinal Disorders in Obese Children

Recruiting
N/A
180
RoW
Life style intervention program
Meir Medical Center
Functional Gastrointestinal Disorders, Obesity, Childhood
09/24
11/24
Jarchowsky, Osnat
XPORT-MM-028, NCT04414475 / 2020-000821-22: A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM

Recruiting
2
141
Europe, RoW
Selinexor, KPT-330, XPOVIO, Dexamethasone, Decadron, Bortezomib, Velcade, Pomalidomide, Imnovid
Karyopharm Therapeutics Inc
Multiple Myeloma, Refractory
06/24
06/25
Cattalini, Marco
NCT04527380 / 2018-000681-10: A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Active, not recruiting
3
100
Europe, RoW
Ixekizumab, LY2439821, Adalimumab
Eli Lilly and Company
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
02/24
04/28
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
10/25
10/25
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
12/30
12/30
NCT06305611: European and North Indian Cohort of KaWasaki dIsease

Recruiting
N/A
103
Europe, RoW
Meyer Children's Hospital IRCCS
Kawasaki Disease
07/24
10/24
NCT06273748: RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age

Recruiting
N/A
290
Europe, US
Meyer Children's Hospital IRCCS
Uveitis
02/32
05/32
AIDA, NCT05200715: AutoInflammatory Disease Alliance Registry

Recruiting
N/A
3500
Europe, US, RoW
No intervention is foreseen by the protocol.
University of Siena
Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome, Still Disease, Autoinflammatory Syndrome, Unspecified, Uveitis, Scleritis, Vexas Syndrome
08/23
08/30
Maimon-Rabinovich, Natalie
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Recruiting
N/A
2000
Europe, US, RoW
Plasma sample collection
OncoHost Ltd.
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma
10/29
10/29
Mishaly, Moshe
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Recruiting
N/A
2000
Europe, US, RoW
Plasma sample collection
OncoHost Ltd.
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma
10/29
10/29
Roth, Idit Lachover -
NCT02785679: The Influence of Early and Continuous Exposure of Infants to Cow's Milk Formula on the Prevention of Milk Allergy

Recruiting
N/A
2500
RoW
cow's milk formula
Meir Medical Center, Schneider Children's Hospital
Cow Milk Allergy, Newborns
08/21
12/21
NCT05080127: The Feasibility of Systemic Reaction After Contact Exposure to the Allergenic Food in Children With Known Food Allergy

Recruiting
N/A
600
RoW
application of the allergenic food
Meir Medical Center
Food Allergy, Quality of Life
07/23
12/23
Furuya, Ken
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B

Active, not recruiting
3
859
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Chronic Hepatitis B, Hepatitis B, Chronic
11/25
05/26
dichtwald, sara
NCT04771793: Physical Restraint of Critically Ill Patients

Completed
N/A
992
RoW
new physical restraint protocols
Meir Medical Center
Delirium
03/23
03/23
NCT04996524: Epidural vs. Systemic Analgesia in the Intensive Care Unit

Completed
N/A
647
RoW
epidural analgesia
Meir Medical Center
Patients With Acute Pain Admitted to the Intensive Care Unit
04/23
04/23
NCT04740333: Prognostic Impact of Admission Glucose Level in Septic Patients Admitted to the Intensive Care Unit

Completed
N/A
224
RoW
No intervention- observational study
Meir Medical Center
Sepsis
02/24
02/24
NCT04983615: Opioid vs. Benzodiazepine-based Sedation for Mechanically Ventilated Patients in the Internal Medicine Ward

Recruiting
N/A
50
RoW
fentanyl-based sedation, midazolam-based sedation
Meir Medical Center
Mechanically Ventilated Patients
08/24
08/25
NCT04992689: Increasing Insulin Resistance as a Predictor of Impending Bacteremia

Completed
N/A
113
RoW
Meir Medical Center
Acquired ICU Bacteremia
01/24
01/24
NCT05924126: Empiric Antibiotic Treatment for Septic Patients in the Intensive Care Unit

Recruiting
N/A
155
RoW
empiric antibiotic therapy
Meir Medical Center
Septic Patients Admitted to the ICU
09/25
09/25
Bauer, Tzofia
NCT04325451: Comprehending Atopic Risk Elements

Active, not recruiting
N/A
252
RoW
MYOR Ltd., Meir Medical Center, The Baruch Padeh Medical Center, Poriya
Atopic Dermatitis
05/23
05/24
Kuchuk, Iryna
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Omelchenko, Alex
BIO|STREAM HF, NCT03366545: Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

Recruiting
N/A
3000
Europe, Japan, RoW
Cardiac Resynchronization Therapy (CRT)
Biotronik SE & Co. KG
Heart Failure
12/24
06/25
NCT04613544: Assess Safety, Efficacy and Usability of Application for Atrial Fibrillation Vocal Marker

Recruiting
N/A
400
RoW
Voice Assist Arrhythmia Monitoring (VAAM)
Cardiokol Ltd
Atrial Fibrillation
08/21
12/21
Kutiel, Talia Shentzer
SPRINT, NCT04256707 / 2021-000617-16: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Recruiting
1/2
120
RoW
Selinexor 100 mg, Xpovio®, Docetaxel, Taxotere®, Pembrolizumab, Keytruda®, FOLFIRI, Selinexor 40 mg, Selinexor 80 mg, Selinexor 60 mg
Karyopharm Therapeutics Inc
Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors
03/25
03/25
Dykan, Yair
NCT04760301: Local Tranexamic Acid During Vaginal Hysteractomy to Reduce Blood Loss

Recruiting
N/A
70
RoW
local tranexamic acid injection, Hexakapron, local normal saline injection to cervix, IV 1 g tranexamic acid, IV 1 g normal saline
Meir Medical Center
Blood Loss
01/22
01/22
Diamant, Avital
NCT05782296: Noninvasive Monitoring of Uterine Activity and Fetal Heart Rate

Recruiting
N/A
100
US, RoW
TrueLabor
OB-Tools Ltd.
Fetal Heart Rate or Rhythm Abnormality Affecting Newborn During Labor, Uterine Contractions, Obstetric Complication
04/24
04/24
Einbinder, Yael
NCT04808011: A Single Arm, Multi-Center Study To Evaluate The Intelligent Dialysis Assistant (IDA)

Recruiting
N/A
20
RoW
Intelligent Dialysis Assistant (IDA)
liberDi Ltd.
Chronic Kidney Disease Stage 5
12/23
12/23
Nemets, Anatoly
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
XPORT-MM-028, NCT04414475 / 2020-000821-22: A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM

Recruiting
2
141
Europe, RoW
Selinexor, KPT-330, XPOVIO, Dexamethasone, Decadron, Bortezomib, Velcade, Pomalidomide, Imnovid
Karyopharm Therapeutics Inc
Multiple Myeloma, Refractory
06/24
06/25
Abadi, Uri
FLMRD, NCT04934930: Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

Recruiting
2
40
RoW
Bendamustin, Ribomustin, Obinutuzumab, Gazyva
Meir Medical Center, Rabin Medical Center, Tel-Aviv Sourasky Medical Center, Assuta Ashdod Hospital, Ziv Medical Center
Follicular Lymphoma
08/25
08/25
HLH, NCT05882175: Prospective Validation of the OHI Index

Recruiting
N/A
300
RoW
Meir Medical Center, Children's Hospital Medical Center, Cincinnati, Rabin Medical Center, Sheba Medical Center, Schneider Children's Medical Center, Israel
HLH, Hemophagocytic Lymphohistiocytoses, Hemophagocytic Syndrome, Hematologic Malignancy, Hematologic Neoplasms
03/25
03/26
Ohana, Nissim
NCT03024008: Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II

Recruiting
1/2
20
RoW
BonoFill-II
BonusBio Group Ltd
Bone Fracture
06/22
09/22
Mosenkis, Nachum Bruce Benjamin
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
01/25
12/26
Bar-Shai, Amir
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Recruiting
3
576
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
IMPAHCT, NCT05036135: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Active, not recruiting
2/3
462
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics
Pulmonary Arterial Hypertension
12/24
01/25
NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Recruiting
2
120
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
11/24
12/24
NCT06201728: The Effect of Asthma Flare-up Clinic After Exacerbation

Enrolling by invitation
N/A
230
RoW
Follow-up in a flare-up clinic
Tel-Aviv Sourasky Medical Center, AstraZeneca
Asthma, Asthma Attack
09/26
09/26
Arkonac, Burak M
NCT04221815: IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

Recruiting
N/A
3100
Europe, US, RoW
Eagle Eye Platinum digital IVUS catheter with optional SyncVision, Resolute Onyx Drug Eluting Stent, Onyx Frontier Drug Eluting Stent, Onyx TruStar Drug Eluting Stent, Onyx TruCor Drug Eluting Stent
Medstar Health Research Institute
Atherosclerosis
04/27
08/27
Marino, Achille
NCT04527380 / 2018-000681-10: A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Active, not recruiting
3
100
Europe, RoW
Ixekizumab, LY2439821, Adalimumab
Eli Lilly and Company
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
02/24
04/28
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
10/25
10/25
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
12/30
12/30
Kushnir, Igal
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
Meister, Gal
NCT05332132: Ex Vivo Study of the Heracure Device for Intra-uterine Morcellation After Vaginal or Laparoscopic Hysterectomy

Recruiting
N/A
10
RoW
Heracure Device
Heracure Medical Ltd.
Vaginal or Laparoscopic Hysterectomy
07/22
12/22
Kaizler, Aisa
NCT05332132: Ex Vivo Study of the Heracure Device for Intra-uterine Morcellation After Vaginal or Laparoscopic Hysterectomy

Recruiting
N/A
10
RoW
Heracure Device
Heracure Medical Ltd.
Vaginal or Laparoscopic Hysterectomy
07/22
12/22
Elinor, Or
LoDAC, NCT05698966: Low Dose Antenatal Corticosteroids for Late Preterm Delivery

Recruiting
N/A
1510
RoW
we will use reduced dose of acceptable corticosteroids treatment for preterm birth
Rambam Health Care Campus
Respiratory Morbidity, Preterm Labor
01/27
01/28
Machová
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
Assali, Rahim
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
Amashukeli, Medea
NCT05514548: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Active, not recruiting
2
265
Europe, Canada, US, RoW
INV-202, None applicable, Placebo
Inversago Pharma Inc., Worldwide Clinical Trials
Diabetic Kidney Disease
07/24
09/24
liu, xianqiang
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Kenis, Irina
NCT05514548: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Active, not recruiting
2
265
Europe, Canada, US, RoW
INV-202, None applicable, Placebo
Inversago Pharma Inc., Worldwide Clinical Trials
Diabetic Kidney Disease
07/24
09/24
Zoref-Lorenz, Adi
HLH, NCT05882175: Prospective Validation of the OHI Index

Recruiting
N/A
300
RoW
Meir Medical Center, Children's Hospital Medical Center, Cincinnati, Rabin Medical Center, Sheba Medical Center, Schneider Children's Medical Center, Israel
HLH, Hemophagocytic Lymphohistiocytoses, Hemophagocytic Syndrome, Hematologic Malignancy, Hematologic Neoplasms
03/25
03/26
Protsenko, Alexander
NCT06029361: Improvement of Function After Hip Fracture in Geriatric Rehabilitation Unit Via Augmented Reality Device "SELFIT"

Recruiting
N/A
50
RoW
Selfit Device group, Control Group
Meir Medical Center
Hip Fractures
03/24
07/24
Ravid, Dorit
NCT06187948: An Informative Video Before Planned External Cephalic Version

Recruiting
N/A
200
RoW
Video
Meir Medical Center
Breech Presentation
12/26
12/27
Shalev, Hila
NCT06187948: An Informative Video Before Planned External Cephalic Version

Recruiting
N/A
200
RoW
Video
Meir Medical Center
Breech Presentation
12/26
12/27
Mastrogiannis, Dimitrios
NCT05782296: Noninvasive Monitoring of Uterine Activity and Fetal Heart Rate

Recruiting
N/A
100
US, RoW
TrueLabor
OB-Tools Ltd.
Fetal Heart Rate or Rhythm Abnormality Affecting Newborn During Labor, Uterine Contractions, Obstetric Complication
04/24
04/24
Shlomo, Emily Ben
NCT06423690: First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System

Not yet recruiting
N/A
15
Europe, RoW
EAS1 System
Snipe Medical
Lung Cancer
01/25
02/25
 

Download Options